Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6466 to 6480 of 7690 results

  1. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued [GID-TA11119]

    Technology appraisal guidance
    Discontinued

  2. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued [GID-TA10197]

    Technology appraisal guidance
    Discontinued

  3. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued [GID-TA10149]

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued [GID-TA10546]

    Technology appraisal guidance
    Discontinued

  5. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued [GID-TA10355]

    Technology appraisal guidance
    Discontinued

  6. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued [GID-TA10081]

    Technology appraisal guidance
    Discontinued

  7. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued [GID-TA10087]

    Technology appraisal guidance
    Discontinued

  8. Seven day working

    Discontinued [GID-QS10108]

    Quality standard
    Discontinued

  9. Mental health community settings

    Discontinued [GID-SGWAVE0702]

    Safe staffing guideline
    Discontinued

  10. OraQuick® HCV Rapid Antibody Test (discontinued)

    Discontinued [GID-MT117]

    Medical technologies guidance
    Discontinued

  11. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued [GID-MT510]

    Medical technologies guidance
    Discontinued

  12. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued [GID-TA10702]

    Technology appraisal guidance
    Discontinued

  13. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development [GID-TA10577] Expected publication date: 21 April 2021

    Technology appraisal guidance
    In development

  14. Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]

    In development [GID-TA10780] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued [GID-TA10088]

    Technology appraisal guidance
    Discontinued